Custom Antibody Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 577.70 Million |
| Market Size (2029) | USD 916.03 Million |
| CAGR (2024 - 2029) | 9.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Custom Antibody Market Analysis
The Custom Antibody Market size is estimated at USD 577.70 million in 2024, and is expected to reach USD 916.03 million by 2029, at a CAGR of 9.60% during the forecast period (2024-2029).
The surging demand for tailored diagnostics and treatments significantly drives the growth of the custom antibody market. These antibodies play a pivotal role in personalized medicine, customizing treatments based on each patient's distinct genetic makeup, lifestyle, and environmental influences. The increasing adoption of precision medicine in oncology further fuels the demand for custom antibodies. Data from the National Cancer Institute indicates that in 2024, the U.S. anticipates approximately 2,001,140 new cancer cases. Given that custom antibodies can identify specific tumor markers, they are instrumental in the early diagnosis and monitoring of cancer progression.
Additionally, custom antibodies are essential in crafting antibody-drug conjugates (ADCs), which specifically target cancer cells while safeguarding healthy tissues. For example, a September 2024 article in the Nature Journal highlighted the swift expansion of multispecific antibodies; of these, 15 have received clinical approval, 11 are designated for oncology, and over 100 are currently in clinical development. Furthermore, as of 2024, the U.S. FDA has greenlit 13 types of ADCs, with an impressive pipeline of over 200 ADCs in various stages of clinical trials (Source: BMC journal, Molecular Cancer, March 2024). The rising adoption of SNAP-tag technology, next-generation sequencing (NGS), and genomics-based methods further amplifies the demand for custom antibodies in biomarker discovery and companion diagnostics.
The market witnessed a boost during the COVID-19 pandemic, prompting numerous biotech and pharmaceutical firms to pivot towards custom antibody development. In July 2024, AbCellera broadened its collaboration with Eli Lilly, focusing on diverse therapeutic antibodies spanning neuroscience, immunology, and cardiovascular domains. In a parallel effort, ProSci is actively offering custom COVID-19 antibody services, encompassing the development of polyclonal, monoclonal, and single-domain antibodies. The company collaborates with end-users to propel COVID-19 antibody advancements, emphasizing vaccine R&D, crafting recombinant single domains, and producing diagnostic assays, detection kits, and tools for both commercial and research purposes.
Moreover, a December 2023 NCBI research study titled 'Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies' underscored that innovations in antibody engineering, hybridoma technology, and recombinant DNA methods have accelerated custom antibody development. Techniques like phage display and CRISPR-Cas9 are streamlining the swift and precise creation of high-affinity antibodies, boosting custom antibody manufacturing efficiency. Advanced next-generation platforms are not only enhancing the performance of antibody reagents but also expanding their functional scope. Additionally, the gradual rise in the adoption of nanobodies can be attributed to their compactness, exceptional stability, and unique ability to target cryptic epitopes, which remain elusive to traditional antibodies. Given these dynamics, the market is poised for significant growth in the coming years.
Nonetheless, challenges such as the steep production costs of custom antibodies and stringent regulatory frameworks pose hurdles to the market's expansion.
Custom Antibody Market Trends
Recombinant Antibody Segment is Expected to Witness Fastest Growth Over the Forecast Period
Expression systems such as E. coli, yeast, and mammalian cell lines are utilized to synthesize recombinant antibodies. The synthesis process involves transfecting these systems with two plasmids that encode the amino acid sequences for both the light and heavy chains. Compared to traditional methods, recombinant antibodies offer distinct advantages. Their production timeline is significantly shorter. While hybridoma projects can take several months, recombinant antibodies can typically be produced in just a few weeks. Furthermore, recombinant technology leverages molecular biology to engineer antibodies with heightened sensitivity and specificity, surpassing the capabilities of monoclonal antibodies derived from immunized animals.
Additionally, antibodies produced via recombinant DNA technology exhibit enhanced specificity and reduced immunogenicity. These antibodies can be customized for precise binding properties. Such features make them indispensable in precision medicine, particularly in oncology, immunology, and infectious diseases. The rising focus on biologics and biosimilars has further amplified the attention on recombinant antibodies. Advanced techniques like phage display and CRISPR-Cas9 are expediting the engineering, development, and production of high-affinity recombinant antibodies, making the process more time-efficient and cost-effective. For instance, recombinant antibodies have proven effective in treating conditions such as HER2-positive breast cancer. These clear advantages over conventional methods have driven the increasing adoption of recombinant antibodies, fueling market growth.
Moreover, leading companies in the biotechnology and bioservices industries have launched products that significantly enhance the capabilities and applications of custom antibodies, making them more accessible for both research and therapeutic uses. For example, in April 2024, Hytest expanded its Insulin product lineup by introducing recombinant monoclonal antibodies RC3A6 and RC8E2. These chimeric antibodies, which replaced Hytest's original in vivo monoclonal antibodies, promise enhanced consistency and performance. Similarly, Proteintech unveiled its Multi-rAb Recombinant Secondary Antibodies in October 2023. These state-of-the-art secondary antibodies are designed to offer unparalleled specificity and reproducibility in widely used immunoassays. Such strategic product launches are bolstering segment growth.
Given these considerations, the segment for recombinant antibodies is poised for substantial growth in the coming years.
North America is Expected to Dominate the Custom Antibody Market
North America is poised to lead the market, driven by substantial investments in biotechnology and pharmaceutical R&D, coupled with a surging demand for personalized medicine. Collaborations between research institutions and antibody service providers are accelerating the rollout of novel antibody-based solutions. For example, the Center for Therapeutic Antibody Development (CTAD) partners with researchers to craft monoclonal antibodies (mAbs) for both research and commercial applications. Similarly, entities like the National Institutes of Health (NIH), the Canadian Institutes of Health Research (CIHR), and the Howard Hughes Medical Institute are funding studies that utilize custom antibodies to delve into specific biological targets and pathways. These partnerships have heightened the demand for custom antibody services across biomedical research, cancer studies, and the evolution of immunotherapies.
Moreover, supportive government policies and bolstered funding for life sciences research are propelling market expansion. In 2023, the National Institute of Health allocated approximately USD 37.8 billion in extramural research funding, benefiting researchers across all 50 states and the District of Columbia. A significant 83% of the NIH budget is channeled into extramural research via grants, contracts, and awards to universities and research institutions, while about 11% is designated for intramural researchers at NIH-operated facilities. Looking ahead to 2025, NIH anticipates backing research endeavors by over 300,000 professionals across more than 2,800 hospitals, medical schools, universities, and research institutions nationwide. Consequently, both public and private research initiatives emphasizing novel therapeutics and diagnostics have catalyzed investments in custom antibody projects, thereby broadening the market.
In North America, particularly in the U.S., the escalating prevalence of autoimmune diseases is driving the demand for custom antibodies in both research and therapeutic contexts. Autoimmune conditions like rheumatoid arthritis, lupus, multiple sclerosis, and Type 1 diabetes are on the rise, impacting millions in the region. Data from the National Health Council indicates that as of March 2024, approximately 50 million Americans grapple with autoimmune diseases, with an annual increase rate between 3% to 12%. This pronounced health challenge accentuates the focus on developing and leveraging custom antibodies. These antibodies not only refine diagnostic assays but also bolster therapeutic advancements, enhancing disease detection and management. For instance, monoclonal antibodies targeting pathways like TNF-alpha or interleukin-6 (IL-6) have been pivotal in treating rheumatoid arthritis, underscoring their significance in autoimmune disease management.
Moreover, industry leaders such as Thermo Fisher Scientific, Abcam, and GenScript are rolling out sophisticated custom antibody platforms and services, addressing the rising demands of academic researchers, CROs, and pharmaceutical firms. The adoption of technologies like phage display and single B-cell screening has refined antibody selection and affinity, propelling market growth. Additionally, major market players are not just launching new platforms but are also broadening their operational horizons. A case in point: in June 2024, Bio-Rad Laboratories, Inc. unveiled an expansion of its Pioneer Antibody Discovery Platform, now featuring rapid generation and screening of bispecific antibodies through the proprietary SpyLock Technology. Such initiatives are set to further amplify market growth in North America.
Custom Antibody Industry Overview
The custom antibody market is moderately consolidated in nature due to the presence of several major companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold significant market share and are well known include Bio-Rad Laboratories Inc., Cell Signaling Technology Inc.,Genscript, Merck Group, Thermo Fisher Scientific Inc., among others.
Custom Antibody Market Leaders
-
Thermo Fisher Scientific Inc.
-
GenScript
-
Merck KGaA
-
Bio-Rad Laboratories, Inc.
-
Cell Signaling Technology, Inc.
-
Rockland Immunochemicals Inc.
-
Promab Biotechnologies Inc.
-
R&D Systems, Inc.
-
PhosphoSolutions
-
Bio-Techne
*Disclaimer: Major Players sorted in no particular order
Custom Antibody Market News
- January 2024: Adimab, LLC, specializing in therapeutic antibody discovery and engineering technologies, has forged partnerships with ten new entities. These include notable names such as Abogen, Affini-T Therapeutics, the Bill & Melinda Gates Research Institute, Curie.Bio, Forte Biosciences, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Moonlight Bio, and Ono Pharmaceuticals. Furthermore, Adimab has broadened its collaborations with nine existing partners, which feature Kelonia, Novo Nordisk, Santa Ana Bio, and Sensei Biotherapeutics.
- October 2023: Sino Biological has launched its new Center for Bioprocessing (C4B) in Houston, Texas. This hub emphasizes CRO services, particularly in the development and production of customized recombinant proteins and antibodies. The launch of C4B highlights Sino Biological's dedication to expanding its CRO services, further enhancing the already strong offerings at its Beijing headquarters.
Custom Antibody Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Demand for Customized Diagnostic and Therapeutic Treatments
4.2.2 Expanding Biopharmaceutical Research & Development Activities Coupled With Supportive Government Funding
4.2.3 Increasing Usage of Custom Antibodies in Biomarker Indentification & Validation
4.2.4 Technological Advancements in Antibody Production
4.2.5 Rising Prevalence of Chronic and Infectious Diseases
4.3 Market Restraints
4.3.1 High Cost & Time-consuming Development Process Associated with Production of Custom Antibodies
4.3.2 Stringent Regulations
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Service
5.1.1 Antibody Development
5.1.2 Antibody Production & Purification
5.1.3 Antibody Fragmentation & Labeling
5.2 By Type
5.2.1 Monoclonal Antibodies
5.2.2 Polyclonal Antibodies
5.2.3 Recombinant Antibodies
5.2.4 Others
5.3 By Source
5.3.1 Mice
5.3.2 Rabbits
5.3.3 Others
5.4 By Application
5.4.1 Research
5.4.2 Therapeutics
5.5 By Indication
5.5.1 Oncology
5.5.2 Infectious Diseases
5.5.3 Immunology
5.5.4 Cardiovascular Diseases
5.5.5 Neurology
5.5.6 Others
5.6 By End User
5.6.1 Pharmaceutical & Biotechnology Companies
5.6.2 Academic & Research Institutes
5.6.3 Contact Research Organization
5.6.4 Others
5.7 Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East and Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East and Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific Inc.
6.1.2 Genscript
6.1.3 Merck KGaA
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Cell Signaling Technology Inc.
6.1.6 Rockland Immunochemicals Inc.
6.1.7 Promab Biotechnologies Inc.
6.1.8 R&D Systems, Inc.
6.1.9 PhosphoSolutions
6.1.10 Bio-Techne
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Custom Antibody Industry Segmentation
A custom antibody is an antibody that targets a unique antigen that isn't readily available. These are used in several research, diagnostics, clinical and therapeutic applications.
The custom antibody market is segmented into device type, end-user, and geography. By type the market is segmented into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, other types. By source the market is segmented into mice, rabbits, other sources. By application the market is segmented into research and therapeutics. By indication the market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, neurology and other indications. By end user the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contact research organization and other end users. By geography the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts have been done on the basis of value (USD).
| By Service | |
| Antibody Development | |
| Antibody Production & Purification | |
| Antibody Fragmentation & Labeling |
| By Type | |
| Monoclonal Antibodies | |
| Polyclonal Antibodies | |
| Recombinant Antibodies | |
| Others |
| By Source | |
| Mice | |
| Rabbits | |
| Others |
| By Application | |
| Research | |
| Therapeutics |
| By Indication | |
| Oncology | |
| Infectious Diseases | |
| Immunology | |
| Cardiovascular Diseases | |
| Neurology | |
| Others |
| By End User | |
| Pharmaceutical & Biotechnology Companies | |
| Academic & Research Institutes | |
| Contact Research Organization | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Custom Antibody Market Research FAQs
How big is the Custom Antibody Market?
The Custom Antibody Market size is expected to reach USD 577.70 million in 2024 and grow at a CAGR of 9.60% to reach USD 916.03 million by 2029.
What is the current Custom Antibody Market size?
In 2024, the Custom Antibody Market size is expected to reach USD 577.70 million.
Who are the key players in Custom Antibody Market?
Thermo Fisher Scientific Inc., GenScript, Merck KGaA, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Rockland Immunochemicals Inc., Promab Biotechnologies Inc., R&D Systems, Inc., PhosphoSolutions and Bio-Techne are the major companies operating in the Custom Antibody Market.
Which is the fastest growing region in Custom Antibody Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Custom Antibody Market?
In 2024, the North America accounts for the largest market share in Custom Antibody Market.
What years does this Custom Antibody Market cover, and what was the market size in 2023?
In 2023, the Custom Antibody Market size was estimated at USD 522.24 million. The report covers the Custom Antibody Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Custom Antibody Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Custom Antibody Industry Report
Statistics for the 2024 Custom Antibody market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Custom Antibody analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
